FI970825A - Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria - Google Patents

Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria Download PDF

Info

Publication number
FI970825A
FI970825A FI970825A FI970825A FI970825A FI 970825 A FI970825 A FI 970825A FI 970825 A FI970825 A FI 970825A FI 970825 A FI970825 A FI 970825A FI 970825 A FI970825 A FI 970825A
Authority
FI
Finland
Prior art keywords
bioavailability
buffer
increase
pharmaceutical compositions
active compound
Prior art date
Application number
FI970825A
Other languages
English (en)
Swedish (sv)
Other versions
FI970825A0 (fi
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of FI970825A publication Critical patent/FI970825A/fi
Publication of FI970825A0 publication Critical patent/FI970825A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
FI970825A 1994-08-31 1997-02-27 Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria FI970825A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417524A GB9417524D0 (en) 1994-08-31 1994-08-31 Pharmaceutical compositions
PCT/GB1995/002015 WO1996006635A1 (en) 1994-08-31 1995-08-25 Pharmaceutical compositions containing a bile salt and a buffer for increased bioavailability of an active compound

Publications (2)

Publication Number Publication Date
FI970825A true FI970825A (fi) 1997-02-27
FI970825A0 FI970825A0 (fi) 1997-02-27

Family

ID=10760623

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970825A FI970825A0 (fi) 1994-08-31 1997-02-27 Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria

Country Status (13)

Country Link
US (1) US5853748A (fi)
EP (1) EP0769960A1 (fi)
JP (1) JPH10504835A (fi)
KR (1) KR970705406A (fi)
AU (1) AU705123B2 (fi)
CA (1) CA2198721A1 (fi)
FI (1) FI970825A0 (fi)
GB (1) GB9417524D0 (fi)
IL (1) IL115097A0 (fi)
NO (1) NO970894L (fi)
NZ (1) NZ291863A (fi)
WO (1) WO1996006635A1 (fi)
ZA (1) ZA957247B (fi)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830185D1 (de) 1997-05-19 2005-06-16 Repligen Corp Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
CA2329130A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
CA2300892A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US9357797B2 (en) 1999-11-06 2016-06-07 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US20030235629A1 (en) * 1999-11-06 2003-12-25 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US20030003537A1 (en) * 2001-04-30 2003-01-02 Ventana Medical Systems, Inc. Method and composition of matter for enhancing staining of microorganisms
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
KR100937113B1 (ko) 2002-01-16 2010-01-18 아스텔라스세이야쿠 가부시키가이샤 경구흡수 개선용 의약 조성물
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
ATE498395T1 (de) * 2003-12-31 2011-03-15 Cima Labs Inc Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
CA2549642C (en) * 2003-12-31 2012-10-30 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering opiates
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CN101084016A (zh) * 2004-04-15 2007-12-05 克艾思马有限公司 能够容易穿透生物学障碍的组合物
RU2393168C2 (ru) 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1934252B1 (en) * 2005-10-13 2015-06-24 Biocon Limited Process for the preparation of insulin conjugates.
KR100700948B1 (ko) * 2006-05-25 2007-03-28 삼성전자주식회사 이동통신 시스템에서 무선 랜의 다중 채널을 이용하는데이터 전송 장치 및 방법
MX2010003979A (es) 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
CN114224829A (zh) 2014-06-27 2022-03-25 玫帝托克斯股份有限公司 用于减少脂肪的胆酸类与盐类的制剂及用途
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
EP3253401A4 (en) 2015-02-03 2018-11-21 Chiasma Inc. Method of treating diseases
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3231253A1 (en) * 2021-09-07 2023-03-16 Eun Ji Park Pharmaceutical composition comprising large physiologically active substance and excipient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
JPH04149126A (ja) * 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
DE4234537A1 (de) * 1992-10-14 1994-04-21 Hoechst Ag Zubereitung, enthaltend Insulin und polymere Gallensäure

Also Published As

Publication number Publication date
NZ291863A (en) 1998-12-23
WO1996006635A1 (en) 1996-03-07
US5853748A (en) 1998-12-29
IL115097A0 (en) 1996-01-19
EP0769960A1 (en) 1997-05-02
NO970894D0 (no) 1997-02-27
NO970894L (no) 1997-02-27
AU705123B2 (en) 1999-05-13
GB9417524D0 (en) 1994-10-19
AU3351095A (en) 1996-03-22
ZA957247B (en) 1997-02-28
JPH10504835A (ja) 1998-05-12
FI970825A0 (fi) 1997-02-27
MX9701455A (es) 1998-05-31
CA2198721A1 (en) 1996-03-07
KR970705406A (ko) 1997-10-09

Similar Documents

Publication Publication Date Title
FI970825A (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
KR970006279A (ko) 약제학적 활성 성분으로서의 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물
FI973828A (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
ID18663A (id) Komposisi farmasi berlapis enterik
ATE246490T1 (de) Pharmazeutische zusammensetzung von topiramate
EE03177B1 (et) Heterobitsüklilised ühendid, nende saamismeetod ja nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid
PT589843E (pt) Composicoes farmaceuticas contendo ciclosporinas
FI955144A0 (fi) Päällystetyt farmaseuttiset koostumukset
FI973279A (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
FI943571A0 (fi) 1-bentseenisulfonyyli-1,3-dihydro-2H-bentsimidatsol-2-onijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
BR9911871B1 (pt) derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.
EE03852B1 (et) Bensofuraani derivaate sisaldav tahke farmatseutiline kompositsioon
EE200000595A (et) Toimeaine viimine kandjamaatriksisse
EE9500059A (et) Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena
FI951789A0 (fi) Uusia taksaanijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
BR9610530A (pt) Derivados de acriloilguanidina substituíduo com heteroarila e composiç es farmacêuticas contendo os mesmos
ID23187A (id) Bentuk bentuk dosis sertralina lepas tunda
NO20003105L (no) Fenylaminoalkylkarboksylsyre-derivater samt medisinske sammensetninger omfattende slike
FR2686513B1 (fr) Compositions pharmaceutiques aqueuses de cromoglycate sodique.
NO940844D0 (no) Farmasöytisk aktive hydroksykarboksylsyrederivater
ITMI932193A0 (it) Composti ad attivita' antiistaminica per la loro preparazione e composizioni farmaceutiche che li contengono
KR950700743A (ko) 프로스타사이클린류를 활성성분으로서 함유하는 외용 피부치료제 조성물(dermatologic preparation composition containing prostacyclin as active ingredient)
BR9307182A (pt) Composições farmacêuticas de 2-oxindol-1-carboxamidas 3-substituídas